Call us : USA : 1-631-381-2994; Europe : 44-207-097-1828
Mail us : info@creative-biolabs.com
Creative Biolabs CAR-T Blog

Menu

Skip to content
  • Chimeric Antigen Receptor Research
  • TCR Research
  • Oncolytic Virus Therapy Research
  • News

CellRapeutics™ Chimeric Antigen Receptor (CAR) Technology

Creative Biolabs has established CellRapeutics™ Chimeric Antigen Receptor (CAR) Technology platform for CAR construction.

Read More

One-Stop CAR-T Therapy Development Services

Creative Biolabs provides high-quality custom service covering the entire CAR-T therapy development process to best suit our your technical, program and budget requirements

Read More

TCR Modified T Cell Development Services

Creative Biolabs focuses on the field of cancer therapy with a strong basic R & D platform that can help you with TCRs development

Read More

Oncolytic Virus Therapy Development

Creative Biolabs provides customized, standardized, and reliable and high-quality oncolytic virus therapy development services for clients globally.

Read More

TOP 10 Research Advances in 2020 on CAR-T Cells

January 8, 2021Chimeric Antigen Receptor ResearchCancer, CAR-T, CRISPR/Cas9biocart

In recent years, CAR-T cells have shown great potential in experimental research and clinical treatment of various malignant tumors since they are of high specificity and strong anti-tumor immune function, especially inRead More…

CAR-T Therapy Evolution—Application of Non-viral Vector and Gene Knock-in Technology

August 18, 2020Chimeric Antigen Receptor ResearchCAR-T, Gene Delivery System, Gene Knock-in Technology, Non-viral Vectorbiocart

As a precision targeted therapy for tumor treatment, CAR-T (chimeric antigen receptor t-cell immunotherapy) has achieved promising results in clinical tumor treatment with optimization and improvement in recent years. It is cutting-edgeRead More…

The Potential of CAR-Macrophages Therapy in Novel Coronavirus Clearance

August 3, 2020Chimeric Antigen Receptor Research, COVID-19CAR-Macrophage, CAR-T, COVID-19biocart

At present, the vaccine research for the Coronavirus Disease (COVID-19) is in progress, but the drug research and development for severe COVID-19 remains a thorny scientific problem. Up to now, there isRead More…

FDA Approves the First IND Application for Universal CAR-T Therapy Derived from iPSC

July 13, 2020Chimeric Antigen Receptor Research, NewsCAR-T therapybiocart

On July 9th, Fate Therapeutics announced that U.S. Food and Drug Administration has approved the first IND application for iPSC-derived allogeneic CAR-T cell therapy FT819 for the treatment of recurrent/refractory B-cell malignant tumors,Read More…

HLA System and HLA Typing

February 8, 2020HLA TypingHLA, HLA Typingbiocart

The human leukocyte antigen (HLA) system or complex is a group of highly polymorphic genomes on chromosomes that encode major histocompatibility complex (MHC) proteins which are expressed on the surface of cellRead More…

PNAS: Targeting Tox and Tox2 is Expected to Improve the Treatment of Solid Tumors by CAR-T Cell Immunotherapy.

June 26, 2019Chimeric Antigen Receptor Research, NewsCAR-T, NFAT, TOX, TOX2biocart

Ten years ago, scientists announced the development of cancer immunotherapy called chimeric antigen receptor-T cell (CAR-T) therapy: genetically modifying T cells from patients to make them powerful anti-tumor effects, and then infusingRead More…

For the first time! Production of CAR-T cells expressing anti-CD19 without virus and plasmid

April 12, 2019Chimeric Antigen Receptor Research, NewsCAR-T, CD19, non-viral plasmid-freebiocart

Recently, it was announced that LineaRx (a part of Applied DNA Science), a company specializing in next-generation biotherapy, has achieved anti-CD19-CAR (chimeric antigen receptor) expression on human T cells through its proprietaryRead More…

Scientists Found a Novel Strategy to Resist T Cell Failure In CAR-T Cell Therapy

March 2, 2019Chimeric Antigen Receptor Research, NewsCAR-Tbiocart

More and more cancer patients are receiving a promising new treatment called CAR-T cell therapy. In this treatment, the patient’s own T cells are removed from the body and genetically modified toRead More…

Scientists Reveal the Molecular Mechanism of CAR-T Cells in Anti-cancer Effect

February 19, 2019Chimeric Antigen Receptor Research, NewsCAR-T, Molecular Mechanismbiocart

Scientists have been hugely successful in developing a new type of anti-cancer therapy, immunotherapy, over the past decade, a treatment that attacks cancer cells by activating the body’s autoimmune system. One of theRead More…

One CAR-T Therapy Fights against Multiple Childhood Tumors

January 23, 2019Chimeric Antigen Receptor Research, NewsCAR-T, Childhood Tumorsbiocart

Scientists at Stanford University developed a new CAR-T therapy that can eradicate many types of childhood tumors in a mouse study, which was published in Clinical Cancer Research on January 17, furtherRead More…

Posts navigation

  • 1
  • 2
  • 3
  • …
  • 6
  • Next »

Categories

  • Chimeric Antigen Receptor Research
  • COVID-19
  • HLA Typing
  • News
  • Oncolytic Virus Therapy Research
  • TCR Research

Recent Posts

  • TOP 10 Research Advances in 2020 on CAR-T Cells
  • CAR-T Therapy Evolution—Application of Non-viral Vector and Gene Knock-in Technology
  • The Potential of CAR-Macrophages Therapy in Novel Coronavirus Clearance
  • FDA Approves the First IND Application for Universal CAR-T Therapy Derived from iPSC
  • HLA System and HLA Typing

Archives

Contact Us

USA:
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: info@creative-biolabs.com
Europe:
Tel: 44-207-097-1828
Copyright © Creative Biolabs CAR-T Blog
Powered by WordPress , Designed and Developed by templatesnext
MENU
  • Chimeric Antigen Receptor Research
  • TCR Research
  • Oncolytic Virus Therapy Research
  • News